Zydus Lifesciences
Date : 23.02.2025
Zydus
Timeframe : Weekly
Strengths
1 Good profit growth of 32.60% for the Past 3 years.
2 Healthy Interest coverage ratio of 11.85.
3 Maintaining an effective average operating margins of 27.25% in the last 5 years.
4 Company’s PEG ratio is 0.16.
5 Has an efficient Cash Conversion Cycle of 45.65 days.
6 Company has a healthy liquidity position with current ratio of 2.22.
7 The company has a high promoter holding of 74.98%
Latest Update :
RECEIVES FINAL APPROVAL FROM USFDA FOR IBUPROFEN AND FAMOTIDINE TABLETS, 800 MG/26.6 MG
Regards,
Ankur
Zydus
Timeframe : Weekly
Strengths
1 Good profit growth of 32.60% for the Past 3 years.
2 Healthy Interest coverage ratio of 11.85.
3 Maintaining an effective average operating margins of 27.25% in the last 5 years.
4 Company’s PEG ratio is 0.16.
5 Has an efficient Cash Conversion Cycle of 45.65 days.
6 Company has a healthy liquidity position with current ratio of 2.22.
7 The company has a high promoter holding of 74.98%
Latest Update :
RECEIVES FINAL APPROVAL FROM USFDA FOR IBUPROFEN AND FAMOTIDINE TABLETS, 800 MG/26.6 MG
Regards,
Ankur
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.